Phagenesis announces the publication of its recent randomised controlled trial confirming the benefits of Phagenyx®

04 September 2018

Nestlé Health Science's partner Phagenesis, a pioneering leader in the treatment of dysphagia, has announced today the publication of its most recent randomised controlled trial (PHAST-TRAC) in the journal Lancet Neurology. The PHAST-TRAC results confirm that tracheostomised stroke patients with swallowing problems can benefit from treatment with Pharyngeal Electrical Stimulation (PES), a novel therapy based on ground-breaking research. The Phagenyx® system developed by Phagenesis, is an innovative medical device that uses PES to restore the neurological control of swallowing in patients with post-stroke dysphagia.

Please view the full release on the Phagenesis website: http://www.phagenesis.com/general/2194